[go: up one dir, main page]

MX2017009408A - Compuestos antihelminticos, composiciones y metodo para usar los mismos. - Google Patents

Compuestos antihelminticos, composiciones y metodo para usar los mismos.

Info

Publication number
MX2017009408A
MX2017009408A MX2017009408A MX2017009408A MX2017009408A MX 2017009408 A MX2017009408 A MX 2017009408A MX 2017009408 A MX2017009408 A MX 2017009408A MX 2017009408 A MX2017009408 A MX 2017009408A MX 2017009408 A MX2017009408 A MX 2017009408A
Authority
MX
Mexico
Prior art keywords
compounds
compositions
ring
anthelmintic compounds
alkoxyalkyl
Prior art date
Application number
MX2017009408A
Other languages
English (en)
Other versions
MX379304B (es
Inventor
Long Alan
Edward Wilkinson Douglas
Original Assignee
Merial Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Inc filed Critical Merial Inc
Publication of MX2017009408A publication Critical patent/MX2017009408A/es
Publication of MX379304B publication Critical patent/MX379304B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/14Ectoparasiticides, e.g. scabicides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La presente invención se relaciona a compuestos antihelmínticos novedosos de la fórmula (IA) enseguida: en donde, Y se selecciona del grupo que consiste de -H, arilo, cicloalquilo, cicloalquenilo, heteroarilo, heterociclilo, alquilo, haloalquilo y alcoxialquilo; y Z se selecciona del grupo que consiste de arilo, cicloalquilo, cicloalquenilo, heteroarilo, heterociclilo, alquilo, haloalquilo y alcoxialquilo. Las variables Anillo A, Anillo B, Anillo C, X1, X6 y X8 son como se definen en la presente. La invención también se relaciona a composiciones parasiticidas que comprenden los compuestos, y métodos y usos de los compuestos para tratar y prevenir infecciones e infestaciones parasíticas en animales.
MX2017009408A 2015-01-20 2016-01-20 Compuestos antihelminticos, composiciones y metodo para usar los mismos. MX379304B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562105463P 2015-01-20 2015-01-20
PCT/US2016/014148 WO2016118638A1 (en) 2015-01-20 2016-01-20 Anthelmintic compounds, compositions and method of using thereof

Publications (2)

Publication Number Publication Date
MX2017009408A true MX2017009408A (es) 2017-10-02
MX379304B MX379304B (es) 2025-03-11

Family

ID=55299781

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009408A MX379304B (es) 2015-01-20 2016-01-20 Compuestos antihelminticos, composiciones y metodo para usar los mismos.

Country Status (11)

Country Link
US (1) US10597364B2 (es)
EP (1) EP3247701B1 (es)
JP (1) JP6771469B2 (es)
CN (1) CN107257793A (es)
AU (3) AU2016209321B2 (es)
BR (1) BR112017015273A2 (es)
CA (1) CA2973873A1 (es)
ES (1) ES2907461T3 (es)
MX (1) MX379304B (es)
NZ (1) NZ734082A (es)
WO (1) WO2016118638A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
BR112018075734A2 (pt) 2016-06-13 2019-04-02 Gilead Sciences, Inc. composto, composição farmacêutica, método para tratar um paciente com uma doença ou condição mediada pelo menos em parte por fxr, e, uso de um composto.
SMT202100723T1 (it) 2016-07-20 2022-01-10 Novartis Ag Derivati di amminopiridina e loro uso come inibitori selettivi di alk-2
ES2927019T3 (es) 2017-03-28 2022-11-02 Gilead Sciences Inc Combinaciones terapéuticas para el tratamiento de enfermedades hepáticas
GB2579747B8 (en) 2017-08-04 2022-10-05 Skyhawk Therapeutics Inc Methods and compositions for modulating splicing
TWI793151B (zh) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
LT3820573T (lt) 2018-07-10 2023-11-10 Novartis Ag 3-(5-hidroksi-1-oksoizoindolin-2-il)piperidin-2,6-diono dariniai ir jų naudojimas gydyti nuo ikaros šeimos cinko pirštų 2 (ikzf2) priklausomas ligas
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
AR116524A1 (es) * 2018-10-04 2021-05-19 Elanco Tiergesundheit Ag Potenciación de tratamiento de helmintos
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
GB201820626D0 (en) * 2018-12-18 2019-01-30 Univ Of Canterbury Conjugates
DK3911647T3 (da) 2019-01-15 2024-02-26 Gilead Sciences Inc Isoxazol-forbindelse som FXR-agonist og farmaceutiske sammensætninger, der omfatter en sådan
EP3911640A4 (en) 2019-01-18 2022-10-26 Astrazeneca AB PCSK9 INHIBITORS AND METHODS OF USE THEREOF
WO2020163541A1 (en) 2019-02-05 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
KR102913697B1 (ko) 2019-02-05 2026-01-15 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
CN113677344A (zh) 2019-02-06 2021-11-19 斯基霍克疗法公司 用于调节剪接的方法和组合物
CN113661162A (zh) 2019-02-06 2021-11-16 斯基霍克疗法公司 用于调节剪接的方法和组合物
JP2022519906A (ja) 2019-02-19 2022-03-25 ギリアード サイエンシーズ, インコーポレイテッド Fxrアゴニストの固体形態
CA3133100A1 (en) * 2019-03-19 2020-09-24 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic aza-benzothiophene and aza-benzofuran compounds
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
US11129829B2 (en) 2019-06-17 2021-09-28 Skyhawk Therapeutics, Inc. Methods for modulating splicing
MX2022004874A (es) 2019-10-25 2022-05-13 Gilead Sciences Inc Compuestos de modulacion de glp-1r.
PE20230251A1 (es) 2019-11-22 2023-02-07 Incyte Corp Terapia de combinacion que comprende un inhibidor de alk2 y un inhibidor de jak2
KR102863043B1 (ko) 2020-01-29 2025-09-23 길리애드 사이언시즈, 인코포레이티드 Glp-1r 조절 화합물
JP7792915B2 (ja) 2020-04-07 2025-12-26 アステラス エンジニアード スモール モレキュールズ ユーエス インコーポレイテッド Cd38阻害薬
WO2021231892A1 (en) 2020-05-15 2021-11-18 Algen Biotechnologies, Inc. Certain chemical compositions and methods of use thereof
JP2023530316A (ja) 2020-06-16 2023-07-14 インサイト・コーポレイション 貧血の治療のためのalk2阻害剤
WO2022109182A1 (en) 2020-11-20 2022-05-27 Gilead Sciences, Inc. Polyheterocyclic glp-1 r modulating compounds
US12091404B2 (en) 2021-03-11 2024-09-17 Gilead Sciences, Inc. GLP-1R modulating compounds
US12180197B2 (en) 2021-03-11 2024-12-31 Gilead Sciences, Inc. GLP-1R modulating compounds
US11932630B2 (en) 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
MX2023012418A (es) 2021-04-21 2023-10-31 Gilead Sciences Inc Compuestos de modulacion de glp-1r de carboxi-bencimidazol.
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4208254A1 (de) 1992-03-14 1993-09-16 Hoechst Ag Substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel und fungizid
WO1999031072A1 (en) * 1997-12-18 1999-06-24 E.I. Du Pont De Nemours And Company Cyclohexylamine arthropodicides and fungicides
US20020002171A1 (en) 2000-01-28 2002-01-03 Chalquest Richard R. Materials and methods for killing nematodes and nematode eggs
WO2002100833A1 (en) 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
US7582645B2 (en) * 2003-10-10 2009-09-01 Bayer Pharmaceuticals Corporation Pyrimidine derivatives for treatment of hyperproliferative disorders
WO2005113494A2 (en) * 2004-05-07 2005-12-01 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
DE102005032838A1 (de) * 2005-07-14 2007-02-08 Merck Patent Gmbh Mischung von Onium-Alkylsulfonaten und Onium-Alkylsulfiten
JPWO2007063839A1 (ja) * 2005-11-30 2009-05-07 塩野義製薬株式会社 シクロヘキサン誘導体
TW200938203A (en) 2007-12-17 2009-09-16 Intervet Int Bv Anthelmintic agents and their use
TW201041868A (en) 2009-03-20 2010-12-01 Intervet Int Bv Anthelmintic agents and their use
TW201111358A (en) 2009-06-18 2011-04-01 Intervet Int Bv Anthelmintic agents and their use
US8575168B2 (en) * 2009-10-09 2013-11-05 Irm Llc Compounds and compositions as modulators of GPR119 activity
AU2011253058A1 (en) 2010-05-13 2012-12-06 Amgen Inc. Heteroaryloxycarbocyclyl compounds as PDE10 inhibitors
WO2011143495A1 (en) * 2010-05-13 2011-11-17 Amgen Inc. Heteroaryloxyheterocyclyl compounds as pde10 inhibitors
EP2468096A1 (en) 2010-12-21 2012-06-27 Intervet International BV Anthelmintic combinations
US8530461B2 (en) * 2011-12-29 2013-09-10 Boehringer Ingelheim International Gmbh Azetidine derivatives
PL2882733T3 (pl) * 2012-08-08 2017-10-31 Elanco Tiergesundheit Ag Podstawione azyny jako pestycydy
KR102151832B1 (ko) * 2012-11-20 2020-09-03 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 구충제 화합물 및 조성물 및 이의 사용 방법
CA2904641C (en) * 2013-03-12 2021-07-20 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
CA2926700C (en) 2013-11-18 2018-03-20 Novartis Tiergesundheit Ag Pyridyl, pyrimidinyl and phenyl compounds and their use in the control of parasites
EP3145925B1 (en) 2014-05-19 2020-11-04 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic compounds

Also Published As

Publication number Publication date
CA2973873A1 (en) 2016-07-28
AU2020204400A1 (en) 2020-07-30
AU2016209321A1 (en) 2017-08-17
AU2019202773B2 (en) 2020-07-02
AU2019202773A1 (en) 2019-05-16
JP6771469B2 (ja) 2020-10-21
EP3247701A1 (en) 2017-11-29
US10597364B2 (en) 2020-03-24
US20180009754A1 (en) 2018-01-11
MX379304B (es) 2025-03-11
AU2016209321B2 (en) 2019-05-09
NZ734082A (en) 2019-01-25
EP3247701B1 (en) 2021-09-22
WO2016118638A1 (en) 2016-07-28
CN107257793A (zh) 2017-10-17
ES2907461T3 (es) 2022-04-25
JP2018502877A (ja) 2018-02-01
BR112017015273A2 (pt) 2018-01-09

Similar Documents

Publication Publication Date Title
MX2017009408A (es) Compuestos antihelminticos, composiciones y metodo para usar los mismos.
MX2019003112A (es) Compuestos antihelminticos y composiciones y metodo de uso de los mismos.
CL2019001744A1 (es) Derivados de benzoxazol como inmunomoduladores.
CO2017013229A2 (es) Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril)piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares
CU20170162A7 (es) Derivados de fenil-tieno(2,3-d)pirimidina-hidroxiácido útiles en el tratamiento del cáncer y enfermedades autoinmunes, método de preparación de los mismos y composiciones farmacéuticas que los contienen
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
MX375153B (es) Compuestos antihelminticos.
MX2019012815A (es) Proceso para la preparacion de compuestos de 2,3-dihidrotiazolo[3, 2-a]pirimidin-4-io opticamente activo.
CL2017000786A1 (es) Compuestos de heteroarilo como inhibidores de tirosina-cinasa de bruton (btk) y usos de estos.
DOP2017000149A (es) Compuestos de triazolopirimidina y usos de los mismos
CO6341623A2 (es) Compuestos organicos
CU20170089A7 (es) Derivados de quinazolina utilizados para tratar el vih
CU20180145A7 (es) Compuestos derivados (piperidin-1-il)(piperidin-4-il) metanona, método de preparación de los mismos y composiciones farmacéuticas que los contienen
BR112015004113A2 (pt) 6-aminoácido heteroarila diidropirimidinas para o tratamento e profilaxia da infecção pelo vírus da hepatite b
CR20120328A (es) Compuestos antiparasitarios de dihidroazol y composiciones que comprenden a los mismos
CU24608B1 (es) Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas y métodos para preparar dichos compuestos
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
MX2019009185A (es) Compuesto heterociclico novedoso, su metodo de preparacion y composicion farmaceutica que lo comprende.
MX2019003026A (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2.
CL2018000856A1 (es) Derivados de éter cíclico de pirazolo[1,5-a]pirimidin-3-carboxiamida.
EA201791396A1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
MX2016006351A (es) Inhibidores de tirosina cinasa de bruton.
BR112018076734A2 (pt) compostos heterocíclicos anti-infecciosos e usos dos mesmos
EA201791397A1 (ru) СВЯЗАННЫЕ С ГЕТЕРОЦИКЛИЛАМИ ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ
CO2017007074A2 (es) Sintesis total de trioxacarcina dc-45-a2 y preparación de analogos de trioxacarcina